Future-proof data handling: Insilico releases the Insilico Data Cleaner, a solution for advanced model-based data curation

(Stuttgart) Insilico Biotechnology AG launches new data connectivity solution for coping with increased demand for predictive solutions in biologics manufacturing and process development.

An increasing amount of data from manufacturing and development in the biopharma industry is made available due to the advancement of data analysis and data collection tools. While capitalizing on the value of the data across projects offers a huge potential for reducing time and costs in manufacturing and development, data is often associated with systematic errors. These errors pose a high risk of false predictions, thus wrong decisions are made.

This is where Insilico’s solution comes into play by combining both biochemical network models and statistical methods. This new combination makes analysis, diagnosis and curation of systematic errors possible. Additionally, it allows merging of dynamic measuring streams of variable data density and frequency. The resulting curated data streams are then readily usable in applications that demand high data quality, such as the Machine-Learning workflows for Digital Twins. Consequently, these curated data streams allow a high predictive quality of Digital Twins in manufacturing and process development.

Klaus Mauch, CEO of Insilico, says “Although there has been a rapid growth in data production in the biopharma industry recently, errors in these data can lead to wrong decisions. Automatic error diagnosis is now possible using our solution. The Insilico Data Cleaner provides the biopharmaceutical industry with unique error diagnosis features leading to the most accurate predictions that these data can offer”.

About Insilico
Insilico Biotechnology AG develops and delivers predictive Digital Twins to advance biopharmaceutical process development and manufacturing. Insilico Digital Twins of cell culture processes lead to superior productivity, product quality and process robustness. Groundbreaking predictive power is achieved by exploiting process data using artificial intelligence and biochemical networks. As a result, Insilico’s unique approach substantially reduces experimental effort, costs of goods and time to market. Leading biopharmaceutical companies worldwide use Insilico Digital Twins for cell line development, media design and process control. Founded in 2001, Insilico Biotechnology is a privately held company based in Stuttgart, Germany.

Contact
Caroline Shafik
Public Relations Manager
Insilico Biotechnology AG
press@insilico-biotechnology.com

If you don't want to receive further company news of Insilico Biotechnology AG please send us an e-mail: info@zeeb.info